Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ascentage Pharma Group International ( (HK:6855) ) has issued an update.
Ascentage Pharma reported a significant revenue increase of 342% in 2024, driven by Takeda’s option payment and strong sales of olverembatinib in China. The company completed a U.S. IPO on Nasdaq, raising $132.5 million, and advanced its clinical programs with ten registrational trials underway, including two FDA-cleared trials. The acceptance of lisaftoclax for NDA review with Priority Review designation in China marks a pivotal step for the company, highlighting its commitment to oncology innovation and expanding its global footprint.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a global, integrated biopharmaceutical company focused on discovering, developing, and commercializing therapies for unmet medical needs, particularly in hematological malignancies.
YTD Price Performance: -19.03%
Average Trading Volume: 3,448,995
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.64B
Learn more about 6855 stock on TipRanks’ Stock Analysis page.